#65 Notable Clinical Interest
Emerging findings or policy developments worth monitoring closely.
Older adults currently using cannabis for sleep, pain, or anxiety should discuss their use openly with their physician, because the risk-benefit calculation shifts meaningfully with age, existing medications, and overall health status.
Research exploring the relationship between cannabis use and mental health outcomes in older adults adds an important layer to how clinicians should approach geriatric care, where the interplay between substances and cognitive or emotional health is particularly complex. Older adults metabolize cannabinoids differently than younger populations, face greater polypharmacy risks, and may be more vulnerable to psychiatric side effects including anxiety, dysphoria, and cognitive disruption. Thoughtful geriatric assessment must account for cannabis use patterns, product types, and dosing rather than treating cannabis as a uniform exposure across all age groups.
“Correlation between rising cannabis use and poor mental health outcomes tells us something worth investigating, but it does not tell us whether cannabis is driving distress or whether people in distress are turning to cannabis, and conflating the two is a clinical mistake.”
While observational studies linking cannabis use to poor mental health outcomes warrant serious consideration, the relationship between cannabis and psychiatric symptoms remains complex and bidirectional. Older adults represent a particularly vulnerable population due to age-related changes in cannabinoid metabolism, polypharmacy concerns, and baseline cognitive changes that can complicate symptom attribution. Clinicians should conduct thorough psychiatric histories to distinguish between cannabis use as a potential causative factor versus self-medication for underlying mood or anxiety disorders. Given the heterogeneity of cannabis products, dosing regimens, and individual patient factors, treatment decisions require individualized assessment rather than categorical avoidance. Future research should employ longitudinal designs with validated mental health measures to clarify causality and identify which patient populations face genuine risk versus those who may derive therapeutic benefit.
๐ฌ Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan โ
Want to discuss this topic with other patients and caregivers? Join the forum discussion โ
Have thoughts on this? Share it: